Navigation Links
Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
Date:12/5/2007

CAMBRIDGE, Mass, Dec. 5 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that the company has completed enrollment of a phase 2 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy. Data from this study are expected to provide substantial evidence for expanding the current product label into adult AML.

"We are very pleased to have reached this milestone and to have done so in a timeframe that we expect will allow us to present preliminary data at ASCO next spring," stated Mark Enyedy, president of Genzyme Oncology. "The completion of patient enrollment in this clinical study is another important step in our plan to broaden the Clolar label to benefit a larger patient population and address multiple lines of adult AML."

Genzyme has held preliminary discussions with the U.S. Food and Drug Administration in advance of submitting a supplemental new drug application (sNDA) for clofarabine as an initial treatment in older adults with AML. The company expects to file this sNDA in the second half of next year.

Significant Unmet Medical Need

The clinical trial, known as CLASSIC II, is designed to address a high unmet medical need among older AML patients who currently have limited treatment options. According to the American Cancer Society, each year approximately 6,500 people over the age of 60 are diagnosed with AML in the U.S. The median survival for those receiving therapy can vary from one to thirteen months, and the five-year survival rate over the past three decades remains at less than 15 percent. Old
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  TeamHealth Medical Call ... triage and nurse advice lines, announces its newly ... physician, nursing and administrative leaders, provides clinical expertise ... and cost-effective services for hospital clients, physician clients ... healthcare system evolves, it,s imperative to continuously advance ...
(Date:5/23/2013)... -- More than half of women diagnosed with early ... still have excellent outcomes. To educate women, Agendia, Inc. ... sources of online consumer information about breast cancer genomic ... recently diagnosed women with information sources, to help them ... "We anticipate these innovative social media campaigns will encourage ...
(Date:5/23/2013)... MONICA, Calif. , May 23, 2013 ... a program that would have required them to obtain ... today by Consumer Watchdog and Whatley Kallas LLC.  ... Diego Superior Court, alleged that Blue Cross,s mandatory mail ... patients, threatening their health and privacy. "This ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
... 20, 2011 Gen-Probe Incorporated (NASDAQ: ... 510(k) application with the US Food and Drug Administration for ... system designed with the flexibility to handle a wide range ... for the PANTHER system on-time is another important milestone in ...
... 2011 Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... proposals considered during the Company,s annual meeting on May 19, ... All six nominees for the Board of ... Advisory vote with respect to the frequency of future "say-on-pay" ...
Cached Medicine Technology:Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument 2Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument 3Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting 2Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting 3
(Date:5/24/2013)... May 24, 2013 This week is ... and their efforts to provide the best emergency care ... of this week is also to educate the public ... of survival. Citizens are the first link, and a ... proper bystander CPR after a cardiac arrest can triple ...
(Date:5/24/2013)... Bethany Beach, Delaware (PRWEB) May 24, 2013 ... Tammy Mushrush has joined the Dayna Feher team at ... Pa., Mushrush made the Delaware resorts her home in ... she has since worked in all aspects of the ... operations, and for the past 12 years, a licensed ...
(Date:5/24/2013)... 24, 2013 E-Dentists.com has announced the ... with JD Media Surge, a leading medical Internet marketing ... SEO analysis service will focus on providing dentists the ... engines for their competitive keywords. The dental SEO analysis ... recommendations based on what their competitors are doing right. ...
(Date:5/24/2013)... Let’s face it: very few are luckily ... the majority of people to be uncomfortable with the color ... coffee addiction or simply genetics, yellowish or stained teeth suppresses ... , Herald Square Dental is proud to announce ... Venus White Max. , Teeth become discolored for a ...
(Date:5/24/2013)... May 24, 2013 Mr. Brian Su, ... 3rd Annual EB-5 Investment Summit: Dealmakers Conference in Long ... will focus on exploring alternative finance through EB-5 immigrant ... legal and economic information, and updates to project developers, ... EB-5 industry. , "Our goal is to assist ...
Breaking Medicine News(10 mins):Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Brian Su Organizes 3rd Annual EB-5 Investment Conference in Long Beach, California 2
... ... ... contributions of voluntary plasma donors and the issue of treating critically ill ... proclaimed August "Plasma Protein Therapies Month" in the Lone Star State. , , ,"Patients ...
... ... on top of current events in the health care industry. , ... Seattle, Washington (PRWEB) August 19, 2009 -- Today, All Allied Health Schools ... helps students keep up with the latest developments in the health care industry--and how these changes ...
... , ANN ARBOR, Mich., Aug. 19 The median profit ... of 2008 to 3.1 percent in the first quarter of 2009, according ... , The recovery has been broad-based, with all classes ... major teaching hospitals -- showing positive median margins. , ...
... ... the Causes of this Growing Trend , ... Jacksonville, Fla. (Vocus) August 18, 2009 -- A recent National Institute of Health ... the growing popularity of alternative therapies for both healthcare treatment and prevention. ...
... A nearly two-decade trend that is stripping away employer-provided ... continue and could soon hit an even deeper pool ... Illinois elder law expert warns. Richard L. Kaplan ... largely from a 1992 change in accounting standards that ...
... , NEW YORK, NY, Aug. 18 /PRNewswire-FirstCall/ - (OTCBB: ... that identifies, acquires, and develops novel drug targets that ... Whiteman as its Chief Executive Officer. , Mr. Whiteman, ... London School of Economics . He will provide ...
Cached Medicine News:Health News:Plasma protein Therapies Association Focuses Attention on Donors and Facilities 2Health News:Plasma protein Therapies Association Focuses Attention on Donors and Facilities 3Health News:All Allied Health Schools Launches "Health Care Community" 2Health News:All Allied Health Schools Launches "Health Care Community" 3Health News:Thomson Reuters Study Finds Impact of Recession Easing on U.S. Hospitals 2Health News:Thomson Reuters Study Finds Impact of Recession Easing on U.S. Hospitals 3Health News:Alternative Therapies And Their Growing Popularity 2Health News:Alternative Therapies And Their Growing Popularity 3Health News:Alternative Therapies And Their Growing Popularity 4Health News:Retirees' health-care benefits at risk, study warns 2Health News:Retirees' health-care benefits at risk, study warns 3Health News:GENova names Aaron Whiteman as CEO 2Health News:GENova names Aaron Whiteman as CEO 3
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With tubular ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
Medicine Products: